Utilizing the Signatera test, early detection of MRD has become a powerful tool for improving cancer management outcomes.
MRD measures ctDNA, a type of cell-free DNA that can be detected and measured in the body’s circulatory system. Accurate identification and quantification of ctDNA in the body can be used to indicate that there are cancer cells present, even after treatment. MRD detection with Signatera is different from traditional uses of ctDNA (therapy selection, asymptomatic cancer screening), because it uses a personalized genetic test, informed by the patient’s own tumor mutation signature.
Facebook
Twitter
LinkedIn
Forward